Top

Published in:

01-12-2013 | Case report

Bevacizumab

Deep vein thrombosis: case report

Published in: Reactions Weekly | Issue 1/2013

Excerpt

A woman [age not stated] with ovarian cancer developed deep vein thrombosis within 3 weeks of receiving bevacizumab [dosage, route and outcome not stated]. The woman was identified in a retrospective analysis of 149 patients who developed toxicities while receiving at least one dose of bevacizumab. …

Stelts SD, et al. Dose adjustments are problematic in common toxicities of bevacizumab. Journal of Thoracic Oncology 6 (Suppl. 2): S1313-S1314 abstr. p3.219, No. 6, Jun 2011 - USA

Title: Bevacizumab
Deep vein thrombosis: case report
Publication date: 01-12-2013
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2013
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-013-7708-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bevacizumab

Deep vein thrombosis: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2013

Being your own worst enemy: ADRs related to self-medication

Diclofenac

Codeine phosphate/ramipril

Amoxicillin/ampicillin

Acetazolamide

Capecitabine, clobazam: risk of SJS/TEN